Dorian LPG
LPG
Ermenegildo Zegna NV
ZGN
Halozyme Therapeutics
HALO
4
DexCom
DXCM
5
Workday
WDAY
(Q1)Mar 28, 2025 | (FY)Jan 3, 2025 | (Q4)Jan 3, 2025 | (Q3)Sep 27, 2024 | (Q2)Jun 28, 2024 | (Q1)Mar 29, 2024 | (FY)Dec 29, 2023 | (Q4)Dec 29, 2023 | (Q3)Sep 29, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -1.52%5.13B | 21.33B | 5.52B | 7.67%5.29B | 12.91%5.3B | 16.55%5.21B | 13.81%19.42B | 16.64%5.34B | 15.76%4.92B | 13.49%4.69B |
Operating revenue | -1.52%5.13B | --21.33B | --5.52B | 7.67%5.29B | 12.91%5.3B | 16.55%5.21B | 13.81%19.42B | 16.64%5.34B | 15.76%4.92B | 13.49%4.69B |
Cost of revenue | -2.10%3.78B | 15.8B | 4.13B | 7.34%3.87B | 12.35%3.94B | 16.88%3.86B | 17.89%14.31B | 17.22%3.89B | 18.22%3.61B | 20.61%3.51B |
Gross profit | 0.15%1.35B | 5.52B | 1.4B | 8.57%1.42B | 14.57%1.36B | 15.61%1.35B | 3.78%5.11B | 15.13%1.45B | 9.46%1.31B | -3.34%1.19B |
Operating expense | -14.95%791M | 3.45B | 669M | 11.59%924M | 12.33%884M | 20.31%930M | 3.00%3.09B | -7.77%700M | 11.59%828M | 5.78%787M |
Selling and administrative expenses | -18.90%502M | --2.15B | ---625M | 11.59%924M | 12.33%884M | -19.92%619M | -35.92%1.92B | -161.53%-467M | 11.59%828M | 5.78%787M |
-Selling and marketing expense | -7.08%105M | --445M | ---- | ---- | ---- | --113M | --450M | ---- | ---- | ---- |
-General and administrative expense | -21.54%397M | --1.71B | ---1.07B | 11.59%924M | 12.33%884M | -34.54%506M | -50.93%1.47B | ---917M | --828M | 5.78%787M |
Research and development costs | -1.75%112M | --515M | ---- | ---- | ---- | --114M | --480M | ---- | ---- | ---- |
Depreciation amortization depletion | -10.15%177M | --779M | ---- | ---- | ---- | --197M | --687M | ---- | ---- | ---- |
-Depreciation and amortization | -10.15%177M | --779M | ---- | ---- | ---- | --197M | --687M | ---- | ---- | ---- |
Operating profit | 33.73%559M | 2.08B | 728M | 3.34%495M | 19.00%476M | 6.36%418M | 4.98%2.03B | 49.70%753M | 5.97%479M | -17.36%400M |
Net non-operating interest income expense | 14.77%-150M | -675M | -161M | -4.40%-166M | -54.95%-172M | -72.55%-176M | -94.62%-543M | -131.08%-171M | -127.14%-159M | -65.67%-111M |
Non-operating interest expense | -14.77%150M | --675M | --161M | 4.40%166M | 54.95%172M | 72.55%176M | 94.62%543M | 131.08%171M | 127.14%159M | 65.67%111M |
Other net income (expense) | 4.17%50M | 195M | -80M | 26.25%101M | 3.61%86M | -41.46%48M | 30.77%-261M | -586.54%-506M | 111.38%80M | -23.15%83M |
Special income (charges) | 15.00%-34M | ---159M | ---- | ---- | ---- | ---40M | 25.31%-599M | ---- | ---- | ---- |
-Less:Restructuring and merger&acquisition | -57.50%17M | --102M | ---- | ---- | ---- | --40M | --174M | ---- | ---- | ---- |
-Less:Impairment of capital assets | ---- | --38M | ---- | ---- | ---- | ---- | -53.37%374M | ---- | ---- | ---- |
-Gain on sale of business | ---17M | ---19M | ---- | ---- | ---- | --0 | ---51M | ---- | ---- | ---- |
Other non- operating income (expenses) | -4.55%84M | --354M | --79M | 26.25%101M | 3.61%86M | 7.32%88M | -20.47%338M | -16.96%93M | -19.19%80M | -23.15%83M |
Income before tax | 58.28%459M | 1.6B | 487M | 7.50%430M | 4.84%390M | -22.25%290M | -4.08%1.22B | -85.74%76M | 224.61%400M | -29.14%372M |
Income tax | 1,360.00%73M | 85M | 31M | 44.44%26M | 9.52%23M | -85.29%5M | -89.15%23M | -143.10%-50M | 190.00%18M | -61.82%21M |
Net income | 35.44%386M | 1.51B | 456M | 5.76%404M | 4.56%367M | -15.93%285M | 12.91%1.2B | -69.78%126M | 226.91%382M | -25.32%351M |
Net income continuous Operations | 35.44%386M | --1.51B | --456M | 5.76%404M | 4.56%367M | -15.93%285M | 12.91%1.2B | -69.78%126M | 226.91%382M | -25.32%351M |
Minority interest income | 0 | 10M | 3M | 500.00%4M | -50.00%1M | 0.00%2M | -2,800.00%-29M | -3,300.00%-32M | 0.00%-1M | 300.00%2M |
Net income attributable to the parent company | 36.40%386M | 1.5B | 453M | 4.44%400M | 4.87%366M | -16.02%283M | 15.54%1.23B | -62.02%158M | 227.67%383M | -25.90%349M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 36.40%386M | 1.5B | 453M | 4.44%400M | 4.87%366M | -16.02%283M | 15.54%1.23B | -62.02%158M | 227.67%383M | -25.90%349M |
Basic earnings per share | 37.58%2.05 | 7.91 | 2.38 | 4.46%2.11 | 4.89%1.93 | -15.82%1.49 | 16.79%6.47 | -61.93%0.83 | 229.49%2.02 | -24.90%1.84 |
Diluted earnings per share | 37.84%2.04 | 7.87 | 2.37 | 3.96%2.1 | 4.92%1.92 | -15.91%1.48 | 17.30%6.44 | -61.57%0.83 | 229.49%2.02 | -24.38%1.83 |
Dividend per share | 3.45%1.2 | 4.64 | 1.16 | 1.75%1.16 | 1.75%1.16 | 1.75%1.16 | 1.79%4.56 | 1.79%1.14 | 1.79%1.14 | 1.79%1.14 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- |